Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-387.

Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.

Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer. Cancer 2008;112:307-314.

Brenot-Rossi I. Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence. Prog Urol 2015;25:716-717.

Gauthe M, Belissant O, Girard A, et al. PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive. Prog Urol 2017;27:474-481.

Cochet A, Kanoun S, Humbert O, et al. Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment. Cancer Radiother 2014;18:509-516.

Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016;17:727-737.

Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111:543-548.

Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61:961-971.

Williams AK, Martínez CH, Lu C, Ng CK, Pautler SE, Chin JL. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol 2011;60:405-410.

Crouzet S, Blana A, Murat FJ, et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int 2017;119:896-904.

Baty M, Crehange G, Pasquier D, et al. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? when? how? Cancer Radiother 2019;23:541-558.

Mutic S, Dempsey JF. The ViewRay system: Magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol 2014;24:196-199.

Pasquier D, Le Deley M-C, Tresch E, et al. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol. BMJ Open 2019;9:e026666.

Loi M, Di Cataldo V, Simontacchi G, et al. Robotic stereotactic retreatment for biochemical control in previously irradiated patients affected by recurrent prostate cancer. Clin Oncol (R Coll Radiol) 2018;30:93-100.

Leroy T, Lacornerie T, Bogart E, Nickers P, Lartigau E, Pasquier D. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center. Radiat Oncol 2017;12:95.

Jereczek-Fossa BA, Rojas DP, Zerini D, et al. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). Br J Radiol 2019;92:20180494.

Łyczek J, Kawczyńska MM, Garmol D, et al. HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. J Contemp Brachytherapy 2009;1:105-108.

Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013;86:324-329.

Maenhout M, Peters M, van Vulpen M, et al. Focal MRI-guided salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer. Technol Cancer Res Treat 2017;16:1194-1201.

Murgic J, Morton G, Loblaw A, et al. Focal salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiation therapy failure: Results from a prospective clinical trial. Int J Radiat Oncol Biol Phys 2018;102:561-567.

Kukiełka AM, Hetnał M, Dąbrowski T, et al. Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure. Strahlenther Onkol 2014;190:165-170.

Loening SA, Turner JW. Use of percutaneous transperineal 198-Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. The Prostate 1993;23:283-290.

Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.

Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 2010;9:119-125.

Fuller D, Wurzer J, Shirazi R, Bridge S, Law J, Crabtree T, et al. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT. Int J Radiat Oncol Biol Phys 2020;106:291-299.

Acharya S, Fischer-Valuck BW, Kashani R, et al. Online magnetic resonance image guided adaptive radiation therapy: First clinical applications. Int J Radiat Oncol 2016;94:394-403.

Finazzi T, Haasbeek CJA, Spoelstra FOB, et al. Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors. Int J Radiat Oncol 2020;107:270-278.

Fischer-Valuck BW, Henke L, Green O, et al. Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system. Adv Radiat Oncol 2017;2:485-493.

Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol 2015;5:e615-623.

Mbeutcha A, Chauveinc L, Bondiau P-Y, et al. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol 2017;12:49.

Miszczyk L, Stąpór-Fudzińska M, Miszczyk M, Maciejewski B, Tukiendorf A. Salvage cyberKnife-based reirradiation of patients with recurrent prostate cancer: The single-center experience. Technol Cancer Res Treat 2018;17:1533033818785496.

Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 2020; online ahead of print.